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Abstract
Introduction: Sporotrichosis is a rare fungal infection in transplant patients; among these patients, it occurs mostly
in renal transplant patients. Sporothrix schenkii is the primary pathogen responsible. A high index of suspicion is
required to make the diagnosis keeping important differential diagnoses in mind. History of trauma through
recreational or occupational exposure to the fungus may assist in making the diagnosis. Treatment is difficult, with
long-term use of potentially nephrotoxic and cytochrome P450 inhibitor antifungal agents leading to potential
calcineurin inhibitors toxicity. We describe two renal transplant patients presenting with distinct sporotrichosis
infection: “Case 2” being only the second reported case ever of meningeal sporotrichosis. We subsequently review
the general aspects of sporotrichosis, specifically in renal transplant patients as described in the medical literature.
Case presentation: Case 1, a 43-year-old mixed ancestry male patient presented with a non-healing ulcer on the
left arm for 1 year, he was diagnosed with cutaneous sporotrichosis and was successfully treated with itraconazole
monotherapy. Case 2, a 56-year-old mixed ancestry male patient presented with a slow decline in functions,
confusion, inappropriate behavior, rigors and significant loss of weight and appetite over the past 4 months, he was
diagnosed with meningeal sporotrichosis and was successfully treated with a combination of deoxycholate
amphotericin B and itraconazole.
Conclusion: Physicians taking care of renal transplant patients should have a high index of suspicion for
sporotrichosis infection particularly when conventional therapy for common conditions fails. Susceptibility testing is
recommended to identify the most effective antifungal agent and its dose. The slow nature of growth of Sporothrix
schenkii necessitates patients to be on amphotericin B until the time results are available. Finally, there is a need to
be aware of potential drug-drug interactions of the azoles with calcineurin inhibitors and the required dose
adjustments to prevent therapy related adverse events.
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Introduction
Sporotrichosis is a rare fungal infection in transplant pa-
tients and among these patients it occurs mostly in renal
transplant patients. Extracutaneous forms of sporotri-
chosis – including meningeal sporotrichosis – without
skin manifestations and no previous history of traumatic
injuries have been described and are often difficult to
diagnose. We present two renal transplant patients who
presented with sporotrichosis, case 1 with cutaneous
sporotrichosis, the most common presentation, and case
2 with meningeal sporotrichosis, which is exceedingly
rare and is only the second case to have ever been re-
ported in the literature. Both our patients were success-
fully treated with antifungal therapy which included
itraconazole monotherapy for case 1 and a combination
of deoxycholate amphotericin B and itraconazole for
case 2. We subsequently review the general aspects of
sporotrichosis, specifically in renal transplant patients as
described in the medical literature.
Case 1
A forty-three-year-old mixed ancestry male patient known
to our division with end-stage kidney disease (ESKD) due
to crescentic glomerulonephritis underwent a living related
renal transplantation in 2009, with a current baseline
creatinine of 118 μmol/L (64–104 μmol/L) and an
estimated glomerular filtration rate (eGFR) of 58mL/min/
1,73m2 (> 60mL/min/1,73m2). His immunosuppression
regime consists of cyclosporine 150mg twice daily, azathi-
oprine 50mg once daily, and prednisone 10mg once daily.
Other comorbidities include systemic hypertension, well
controlled on amlodipine 5mg once daily, and gastritis,
well controlled with omeprazole 20mg once daily. He pre-
sented in December 2018 with concerns of a non-healing
ulcer on his left arm (Fig. 1c) for the past year which was
nonresponsive to conservative therapy with daily saline
dressings and empiric courses of antibiotics, including
Amoxicillin. He had a history of being employed as a gen-
eral worker in construction performing manual labour
where he reports to have sustained injuries to his fingers
and hands on multiple occasions. He has been working in
the clothing factory for the past 6 years, he does not smoke
or consume alcohol and does not give a history of gardening
or other similar hobbies. The family and environmental his-
tory were unremarkable. Three years post-transplantation
he presented with a non-healing ulcer of his left thumb
which had developed from a nodule on the same digit. He
received treatment in the form of surgical debridement and
daily saline dressings which assisted with ulcer healing. He
also reported features in keeping with nodular lymphangitis
which resolved spontaneously prior to his current presenta-
tion. On physical examination he was clinically well, with a
blood pressure of 116/71mmHg, pulse rate of 72 beats/min
and temperature of 36.0 °C. He had a 2 X 3 cm ulcer on the
posteromedial aspect of his left arm which had a granulated
base with some purulent discharge; his systemic examin-
ation was otherwise unremarkable. With concerns of malig-
nancy post-transplantation, skin biopsies were performed.
These revealed necrotizing granulomatosis with no malig-
nant features. A repeat biopsy in March 2019 isolated Sporo-
thrix schenkii on fungal culture and polymerase chain
reaction (PCR) sequencing and he was subsequently initi-
ated on oral itraconazole 400mg once daily for four weeks
followed by 200mg once daily as life-long prophylaxis. His
wound healed within 2weeks of commencing treatment, he
has been well since, and follows up regularly at our trans-
plant clinic for review.
Case 2
A fifty-six-year-old mixed ancestry male patient with
end-stage kidney disease due to malignant hypertension
was admitted in December 2018 on account of his
family’s concerns of a slow decline in functions, confu-
sion, inappropriate behavior, rigors and significant loss
of weight and appetite over the past 4 months. He
underwent a deceased donor renal transplantation in
2002 with a baseline creatinine of 91 μmol/L (64–
104 μmol/L) and eGFR of 58 mL/min/1,73m2 (> 60mL/
min/1,73m2). His immunosuppressive regime consisted
of tacrolimus 2 mg twice daily, prednisone 10mg once
daily, and mycophenolate mofetil (MMF) 500 mg twice
daily. He used to work in the South African Police Ser-
vices previously but has been unemployed for over 10
years, he does not smoke or consume alcohol and does
not give a history of gardening or other similar hobbies.
The family and environmental history were unremark-
able. A review of his medical records revealed a remote
history of articular sporotrichosis diagnosed on aspir-
ation of his left wrist joint 2 years prior to his current
presentation, for which he received treatment with oral
itraconazole 200 mg daily for a total duration of 10
months. On physical examination he had a blood pres-
sure of 135/72mmHg, heart rate of 96 beats/minute, re-
spiratory rate of 16 per/minute, temperature of 36.4 °C,
random blood glucose of 12 mmol/L and, he appeared
chronically ill with bilateral temporalis muscle wasting.
His extracellular fluid compartment was contracted, and
he had chronic non-pitting oedema of the lower limbs.
He had symmetrical synovial hypertrophy on the small
joints of his hands without evidence of a destructive ar-
thropathy. Importantly, he did not have any stigmata
suggestive of cutaneous or lymphocutaneous sporotri-
chosis. His sensorium was altered with a Glasgow Coma
Scale of 12/15 (eyes – 4, motor – 5, verbal – 3), neither
meningism nor focal neurological deficits were evident
on the motor and sensory examinations. Examination of
his fundi revealed no evidence of papilloedema. The rest
of his physical examination was unremarkable. His
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work-up revealed patchy alveolar infiltrates on chest
radiography. Computerized tomography of the brain was
essentially normal apart from mild global cerebral atro-
phy and microangiopathic changes. Considering the
history, clinical presentation, laboratory findings
(Table 1) and the high background prevalence of tuber-
culosis in our population, as well as his immunosup-
pressed state, we decided to initiate empiric rifampicin
Fig. 1 a Sporothrix schenkii growth on Saboraud Dextrose agar – 28 °C. b Sporothrix schenkii – typical “cigar” shaped budding yeast cells – 37 °C
(Gram stain from cerebrospinal fluid (CSF), X 100 magnification). a and b: CSF specimen obtained from case 2. c Left arm 2 X 3 cm non-healing
ulcer with a granulated base and some purulent discharge (case 1)
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sparing oral anti-tuberculous therapy (moxifloxacin 400
mg once daily, isoniazid 300 mg once daily, ethambutol
400 mg once daily, pyridoxine 25mg once daily and pyr-
azinamide 1,2 g once daily). The patient’s clinical state
continued to deteriorate despite being on anti-
tuberculous treatment for more than 4 weeks. The diffi-
culty was distinguishing a slow response to anti-
tuberculous therapy in a patient with significant comor-
bidities from a misdiagnosis. Based on his deteriorating
clinical state, previous remote history of articular
Table 1 Clinical and laboratory data (case 2)
Red data signifies an abnormal value
Spp Species
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sporotrichosis, and after reviewing the literature, we
entertained the diagnosis of possible meningeal sporotri-
chosis and subsequently requested investigations specific
for sporotrichosis which was confirmed by PCR in Feb-
ruary 2019. Based on these results (Table 2) we discon-
tinued his anti-tuberculous treatment and MMF and
initiated intravenous deoxycholate amphotericin B
(AMB-d) (0,75 mg/kg/day – adjusted to eGFR) which
was continued for 35 days. Liposomal amphotericin B is
prohibitively expensive in our setting, we therefore opted
to treat him with AMB-d. Following this intensive phase
of daily AMB-d, he showed a slow but favorable re-
sponse to therapy (Table 3) and returned to a level of
functioning that allowed independent out-patient living.
On discharge, the dosing frequency of AMB-d was de-
creased to once weekly, given for a total of 4 doses, due
to concerns of AMB-d related nephrotoxicity. He was
also initiated on oral itraconazole 200 mg twice daily,
which he was to continue for the next 12 months
followed by 200 mg once daily as life-long prophylaxis.
He had been stable and well at the time of this write-up;
he unfortunately passed away at home, while asleep 3
months after discharge, an autopsy was declined by the
family; the cause of death was presumed to be of cardiovas-
cular nature.
Literature review
Sporothrix schenkii (SS) is a thermally dimorphic fungus –
capable of existing as a saprophytic mold at environmental
temperatures (25–30 °C) and a yeast at body temperature
(37 °C) – belonging to the genus Sporothrix. SS is the pri-
mary pathogen responsible for sporotrichosis and spores
of the mold are usually found in soil, damp or decaying
wood and roses, and hence sometimes referred to as rose
gardener’s disease. The fungus is usually inoculated
through the skin and most frequently (95%) involves the
cutaneous and subcutaneous tissues and lymphatics in im-
munocompetent patients. Persons at risk for disseminated
SS are usually immunocompromised, and include, dia-
betics, those with chronic alcoholism, Human Immuno-
deficiency Virus/Acquired Immunodeficiency Syndrome
(HIV/AIDS) and solid organ transplant patients. Zoonotic
transmission from infected cats has been reported in
Brazil and other South American countries where the dis-
ease is endemic [1]. The cutaneous form begins with a
papule at the site of inoculation which may ulcerate or re-
main nodular with surrounding erythema. Drainage fluid
may be odourless and non-purulent or pyogenic in nature,
pain is usually mild with absent systemic symptoms.
Similar lesions occur along the lymphatic drainage
proximal to the index lesion, termed “Sporotrichoid”
Table 2 Specific laboratory testing for Sporotrichosis (case 2)
Red data signifies an abnormal value
PCR Polymerase Chain Reaction
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spread or nodular lymphangitis. Differential diagnoses in-
clude non-tuberculous mycobacterial infection, Nocardia
and Leishmania [2, 3]. The disseminated form can in-
volve various organ systems; including, pulmonary,
osteoarticular, eyes (uveitis), and heart (endocarditis)
[1]. Gullberg et al. [4] reported a recurring case of dis-
seminated sporotrichosis in a renal transplant patient,
involving joints, skin, and the central nervous system.
This required three treatment cycles with systemic
AMB-d. In the second cycle, intra-articular AMB-d was
administered and in the third one, intrathecally.
Immunosuppression was tapered to prevent further re-
lapses. Agarwal et al. [5] reported a case of pyeloneph-
ritis due to SS in a renal transplant patient with a
history of multiple renal calculi and recurrent urinary
tract infections, the patient died in an accident before
appropriate treatment could be initiated. Caroti et al.
[6] reported SS infection in a renal transplant patient
who initially presented with erythematous papulonodu-
lar lesion following trauma to the leg which responded
to treatment with fluconazole. He presented again
seven years later with acute osteomyelitis and gangrene
in the same foot with ulcers. Biopsy of the ulcer re-
vealed SS infection, MMF was discontinued and the pa-
tient responded well to fluconazole with regression of
the lesions. Gewehr et al. [7] report two cases of sporo-
trichosis in renal transplant patients, the first patient
had a prior history of trauma, presented with papular
lesions on the hand and ear, while the second patient
had no history of trauma, presented with generalized
weakness, joint pain and disseminated nodular and ul-
cerated lesions involving the upper and lower extrem-
ities and the trunk. Both these patients were treated
with itraconazole and amphotericin B. Table 4 summa-
rizes cases of sporotrichosis in renal transplant patients
reported in the literature to date.
Discussion
Opportunistic infections are common in organ transplant
patients, where fungal infections comprise 6% of all infec-
tions. Candida species, Aspergillus species and Cryptococ-
cus neoformans are most frequently isolated [9].
Sporotrichosis is rare in transplant patients, and in these
patients, it occurs mostly in renal transplant recipients, al-
though Bahr et al. [10] reported sporotrichosis in a lung
transplant patient and da Silva et al. [11] recently reported
the first case of sporotrichosis in a liver transplant recipi-
ent. After a thorough search of the relevant literature our
case (case 2) is only the second reported case of meningeal
sporotrichosis in a renal transplant recipient, the first case
was reported in 1987 by Gullberg et al. [4]. Our patient
(case 2) differs from the one reported [4] by the way he
presented clinically with features suggestive of tuberculous
meningitis and no stigmata of cutaneous or lymphocuta-
neous sporotrichosis; thus making the diagnosis a
challenge. Patients with meningeal involvement present
with various symptoms, including: fever, headache, neck
stiffness, vomiting, seizures, and altered mentation [1]. Im-
portant differential diagnoses include cryptococcal menin-
gitis and tuberculous meningitis [12]. Investigations
Table 3 Serial laboratory values depicted in relation to initiation of antifungal therapy (case 2)
Neg Negative, CSF Cerebrospinal fluid
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include a LP which is usually lymphocyte predominant
with low CSF glucose and high protein levels. Tissue/CSF
fungal culture is the gold standard and most sensitive
method but may take longer to yield results while fungal
PCR and sequencing can also be utilized to more rapidly
identify SS [3]. Treatment is notoriously difficult given the
paucity of clinical trials and the overlapping nature of the
clinical features and laboratory investigations of this rare
disease with more common aetiologies. Clinical practice
guidelines of the Infectious Disease Society of America
[13] recommend using itraconazole for cutaneous/lym-
phocutaneous involvement at 200mg once daily for up to
2–4 weeks after the lesions have resolved – terbinafine
500mg twice daily can be used as an alternative. Menin-
geal involvement is treated more aggressively with liposo-
mal amphotericin B for at least 4 to 6 weeks at a dose of
3–5mg/kg, followed by itraconazole 200mg twice daily
for at least 1 year. Deoxycholate (conventional) amphoteri-
cin B can be used as an alternative. Itraconazole prophy-
laxis at 200mg once daily is to be continued life-long or
until immunosuppression has been withdrawn. Calcine-
urin inhibitor dosage should be lowered by 33–66% to
maintain the recommended therapeutic levels [14]. The
significant inhibition of the Cytochrome P450 3A4 by the
azoles leads to decreased metabolism with subsequent in-
creased therapeutic levels of CNI’s leading to potential
CNI toxicity. At our unit we reduce the total daily CNI
dose by 66% following the first 24 hours of azole therapy,
and subsequently adjust the dose according to the re-
quired through levels.
Conclusion
Sporotrichosis is a rare opportunistic infection that
occurs mostly in renal transplant patients; it can be
localized (lympho-cutaneous) or involve various organ
systems (disseminated). A high index of suspicion is re-
quired to make the diagnosis with the important differ-
ential diagnoses kept in mind. A history of trauma
through recreational or occupational exposure to the
fungus may assist in making a diagnosis. Treatment is
difficult, with long-term use of potentially nephrotoxic
and Cytochrome P450 3A4 inhibitor antifungal agents,
which necessitate stringent monitoring of therapeutic
drug levels to counteract CNI toxicity.
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Gullberg et al. [4],
1987
50/male Deceased donor Arthritis, meningitis
(four years)
Unknown AMB-d Alive
Agarwal et al. [5],
1994
23/male Living related donor Pyelonephritis (nine months) No None Death
Rao et al. [8],
2002
49/female Deceased donor Nasopharyngeal mass
(six months)
No None Death
Caroti et al. [6],
2010
59/male Unknown Erythematous papular lesion
on the left leg (unknown)
Yes FLZ Alive
P Gewehr et al.
[7], 2013
48/female Deceased donor Plaques and ulcers on the hand
and ear (nine months)
Yes AMB-L; ITZ Alive
53/male Deceased and living
unrelated donors
Arthritis, draining and necrotic
subcutaneous nodules in the
limbs and trunk (one month)
No AMB-L; ITZ; FLZ Alive
This study 43/male Living related donor Non-healing ulcer - left
arm (ten years)
Yes ITZ Alive
54/male Deceased donor Pain and swelling – left wrist
joint (fifteen years)
Unknown ITZ Alive
56/male Deceased donor Constitutional symptoms,
seizures, fluctuating mental
state (seventeen years)
Unknown AMB-d; ITZ Death
AMB-d Amphotericin B deoxycholate, AMB-L Amphotericin lipid complex, FLZ Fluconazole, ITZ Itraconazole
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